AbbVie Inc. $ABBV Shares Bought by Meritage Portfolio Management

Meritage Portfolio Management grew its position in AbbVie Inc. (NYSE:ABBV) by 22.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,872 shares of the company’s stock after purchasing an additional 7,057 shares during the period. Meritage Portfolio Management’s holdings in AbbVie were worth $9,000,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ABBV. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the 2nd quarter valued at $26,000. Spurstone Advisory Services LLC purchased a new position in AbbVie in the second quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the second quarter worth about $36,000. Finally, Delos Wealth Advisors LLC acquired a new position in shares of AbbVie during the second quarter worth about $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV opened at $222.21 on Thursday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The firm has a market capitalization of $392.72 billion, a price-to-earnings ratio of 168.34, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The stock’s fifty day moving average is $226.94 and its 200-day moving average is $216.08.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. UBS Group restated a “neutral” rating on shares of AbbVie in a research note on Tuesday. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. Guggenheim boosted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Finally, Piper Sandler restated an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie says it will build out its presence in the fast-growing obesity-treatment market, leveraging a weight‑loss drug it licensed from Danish biotech Gubra — opens a new growth avenue beyond core franchises. AbbVie plans to build out its presence in obesity market
• Positive Sentiment: AbbVie reached a three‑year drug‑pricing pact with the U.S. administration that includes a $100 billion U.S. R&D/investment pledge and exemptions from certain tariffs — reduces policy/tariff risk and signals regulatory cooperation. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to a ~$5.6B licensing partnership with RemeGen to access a PD‑1xVEGF bispecific oncology candidate — expands oncology pipeline and potential future revenue streams. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: AbbVie is acquiring a drug‑delivery system and an Arizona manufacturing facility from West Pharma and is spending on U.S. manufacturing capacity (including a reported $175M plant) — strengthens supply chain and supports on‑shore production. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Management’s full transcript from the J.P. Morgan Healthcare Conference provides detail on strategy and pipeline positioning — useful for modeling but no single market‑moving surprise in the transcript itself. AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Several analyst/market pieces highlight bullish sentiment and long‑term value arguments for ABBV; these can support momentum but reflect secondary commentary rather than new company facts. Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
• Neutral Sentiment: AbbVie joined industry calls for the FDA to update post‑approval change rules — a regulatory engagement that could benefit manufacturers broadly if successful but is a longer‑term policy push. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Negative Sentiment: The U.S. drug‑pricing agreement includes commitments to lower some U.S. prices and Medicaid impacts — this could weigh on near‑term revenue/margins for affected products even as tariff/other risks are reduced. ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.